Cubist Systematic Strategies, LLC Replimune Group, Inc. Transaction History

Cubist Systematic Strategies, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $267,098 - $504,340	53,313 Added 282.17%	72,207 $649,000
Q1 2024 May 15, 2024	BUY	$6.87 - $9.31 $129,801 - $175,903	18,894 New	18,894 $154,000
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $465,946 - $775,423	-26,656 Reduced 48.52%	28,282 $499,000
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $301,399 - $492,220	17,636 Added 47.28%	54,938 $1.49 Million
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $317,226 - $430,085	20,335 Added 119.85%	37,302 $644,000
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $822,723 - $1.23 Million	-61,766 Reduced 78.45%	16,967 $297,000
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $810,996 - $1.58 Million	53,215 Added 208.54%	78,733 $1.34 Million
Q4 2021 Feb 14, 2022	BUY	$25.43 - $34.25 $209,772 - $282,528	8,249 Added 47.77%	25,518 $692,000
Q3 2021 Nov 15, 2021	BUY	$28.98 - $39.54 $465,244 - $634,775	16,054 Added 1321.32%	17,269 $512,000
Q2 2021 Aug 16, 2021	SELL	$28.5 - $39.37 $915,277 - $1.26 Million	-32,115 Reduced 96.35%	1,215 $47,000
Q1 2021 May 17, 2021	SELL	$30.22 - $45.57 $311,628 - $469,917	-10,312 Reduced 23.63%	33,330 $1.02 Million
Q4 2020 Feb 16, 2021	BUY	$23.5 - $52.65 $965,591 - $2.16 Million	41,089 Added 1609.44%	43,642 $1.67 Million
Q3 2020 Nov 16, 2020	BUY	$18.85 - $27.0 $48,124 - $68,931	2,553 New	2,553 $59,000
Q1 2020 May 15, 2020	SELL	$8.9 - $19.08 $182,725 - $391,731	-20,531 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.61 - $17.21 $238,364 - $353,338	20,531 New	20,531 $295,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.